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Abstract
BACKGROUND—Results from the second CONCORD study (CONCORD-2) indicated that 5-
year net survival for lung cancer was low (range, 10%–20%) between 1995 and 2009 in most 
countries, including the United States, which was at the higher end of this range.
METHODS—Data from CONCORD-2 were used to analyze net survival among patients with 
lung cancer (aged 15–99 years) who were diagnosed in 37 states covering 80% of the US 
population. Survival was corrected for background mortality using state-specific and race-specific 
life tables and age-standardized using International Cancer Survival Standard weights. Net 
survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 
at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, 
Epidemiology, and End Results Summary Stage 2000; and US state.
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RESULTS—Five-year net survival increased from 16.4% (95% confidence interval, 16.3%–
16.5%) for patients diagnosed 2001–2003 to 19.0% (18.8%–19.1%) for those diagnosed 2004–
2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5-
year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state 
from 14.5% to 25.2%.
CONCLUSIONS—Lung cancer survival improved slightly between the periods 2001–2003 and 
2004–2009 but was still low, with variation between states, and persistently lower survival among 
blacks than whites. Efforts to control well established risk factors would be expected to have the 
greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients 
receive timely and appropriate treatment should reduce the differences in survival by race and 
state.
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cancer registries; disparities; lung neoplasms; population-based survival; race; stage; survival; 
trends
INTRODUCTION
In the United States, lung cancer accounts for approximately 14% of all invasive cancers 
diagnosed each year and for 27% of all cancer-related deaths.1 Lung cancer incidence and 
mortality rates vary by sex and race.1,2 Among males, lung cancer incidence peaked in 1982, 
and mortality peaked in 1991.2 Among females, mortality peaked in 2003, and incidence 
peaked in 2006.2 Lung cancer incidence and mortality rates are currently decreasing slowly, 
but the rates are higher among black males than among white males and are lower among 
black females than among white females.1,2 By 2020, the numbers of lung cancer cases and 
deaths in the United States are projected to increase because of the aging white population 
and population growth in the black population.3,4
Population-based cancer survival provides an indicator of the overall effectiveness of the 
health care system to deliver screening, early diagnosis, and evidenced-based treatment 
services to all individuals in the population being served.5 Survival differences between 
populations may be attributable to disparities in access to early diagnosis and optimal 
treatment.6
The second CONCORD study (CONCORD-2) reported survival for patients diagnosed with 
cancer between 1995 and 2009 in 67 countries, enabling comparison of survival of patients 
in the United States with other countries.6,7 The CONCORD-2 study is the largest study to 
date on lung cancer survival, both in the United States and worldwide. Between 1995 and 
2009, 5-year net survival for patients diagnosed with lung cancer was low in most countries 
(range, 10%–20%).6 Survival in the United States was at the higher end of this range.6
In the current study, we conduct a more detailed analysis of US data from the CONCORD-2 
study. We describe and discuss trends in net survival among patients diagnosed with lung 
cancer by race, stage, and state. We also discuss how population-based lung cancer survival 
might be used to help inform comprehensive cancer control.8
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MATERIALS AND METHODS
Data Source
We analyzed the US lung cancer data from the CONCORD-2 study, which included cases 
reported by 37 state-wide cancer registries funded by CDC’s National Program of Cancer 
Registies (NPCR) and/or the National Cancer Institute’s Surveillance Epidemiology and End 
Results Program (SEER), and that covered approximately 80% of the US population and 
consented to the inclusion of their data in the more detailed analyses reported here.7,8 We 
analyzed individual tumor records for adults (men and women, aged 15–99 years) who were 
diagnosed with a primary, invasive cancer of the lung or bronchus (International 
Classification of Diseases for Oncology, third edition,9 topography codes: C34.0–C34.3 and 
C34.8–C34.9) between 2001 and 2009 and were followed until December 31, 2009, 
regardless of whether the patient had had a previous cancer. If a patient was diagnosed with 
2 or more cancers of the lung between 2001 and 2009, then we only considered the first 
cancer in the survival analyses.
We grouped patients by year of diagnosis into 2 calendar periods (2001–2003 and 2004–
2009) to reflect changes in the methods used by US registries to collect Surveillance, 
Epidemiology, and End Results (SEER) Summary Stage 2000 (SS2000) at diagnosis. 
Between 2001 and 2003, most registries coded stage to SS2000 directly from the medical 
records.10 Between 2004 and 2009, all registries derived SS2000 using the Collaborative 
Staging System.11
Survival Analyses
We analyzed net survival by race (all races, black, white), by stage (localized, regional, 
distant, unknown), state, and calendar period of diagnosis. We estimated net survival at 1, 3, 
and 5 years after diagnosis with 95% confidence intervals (CIs), using the Pohar Perme 
estimator.7,12 Net survival can be interpreted as the probability of surviving up to a given 
time since diagnosis, after controlling for other causes of death (background mortality).7 To 
control for wide differences in background mortality between participating registries and 
over time, we constructed life tables of all-cause mortality in the general population of each 
state from the number of deaths and the population, by single year of age, sex, calendar year, 
and, where possible, by race (black or white), using a flexible Poisson model.13 Methods for 
constructing life tables have been published.14
We estimated net survival using 2 different methods, since follow time was different in the 2 
calendar periods. For patients diagnosed between 2001 and 2003, we used the cohort 
approach, because all patients had been followed for at least 5 years by December 31, 2009. 
We used the complete approach to estimate net survival for patients who were diagnosed 
between 2004 and 2009, because 5 years of follow-up data were not available for all 
patients. We estimated net survival for 5 age groups (ages 15–44, 45–54, 55–64, 65–74, and 
75–99 years). We obtained age-standardized survival estimates using the International 
Cancer Survival Standard weights.15 If 2 or more of the 5 age-specific estimates could not 
be obtained, then we present only the pooled, unstandardized survival estimate for all ages 
combined. We identify unstandardized survival estimates using italics in tables.
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We present trends, geographic variations, and differences in age-standardized survival by 
race in bar charts and funnel plots.16 Funnel plots of net survival for the 2 periods (2001–
2003 and 2004–2009) provide insight into the variability of lung cancer survival by race and 
state. They indicate how much a particular survival estimate deviates from the pooled 
estimate for all registries combined, given the precision of each estimate.7,16 The pooled 
estimate for all US registries combined is shown as the “target” (horizontal line) in the 
funnel plot. More details on data and methods are provided in the accompanying article by 
Allemani et al.7
RESULTS
We present the overall results for lung cancer in Tables 1–3. State-specific results are 
reported in Supporting Tables 1–3.
Distribution of Cases by Stage, Race, and Calendar Period
In total, 1,404,724 patients were diagnosed with lung cancer during 2001–2009; of these, 
86.9% were white, and 10.2% were black (Table 1). The proportion of patients diagnosed 
with disease at distant stage increased from 46.8% between 2001 and 2003 to 50.9% 
between 2004 and 2009. In contrast, during the same periods, the proportions of localized 
stage (17.5% and 17.7%, respectively) and regional stage (24.2% and 23.4%, respectively) 
remained relatively stable over time (Table 1). In both calendar periods, the proportion of 
blacks diagnosed with localized stage disease was lower than that for whites, whereas a 
higher proportion of blacks was diagnosed at distant stage. Between 2004 and 2009, the 
proportion of patients diagnosed at each stage ranged between states as follows: localized 
(range, 13.1%–21.9%), regional (20.3%–26.3%), and distant (45.4%–59.4%) (Supporting 
Table 1).
One-Year, 3-Year, and 5-Year Net Survival by Race and Calendar Period
Between 2001 and 2003, the pooled estimate of net survival for all patients combined was 
42.5% (95% CI, 42.4%–42.7%) at 1 year, 21.6% (21.4%–21.7%) at 3 years, and 16.4% 
(16.3–16.5) at 5 years. For patients who were diagnosed between 2004 and 2009, net 
survival had risen to 45.6% (45.5%–45.7%) at 1 year, 24.5% (24.4%–24.6%) at 3 years, and 
19.0% (18.8%–19.1%) at 5 years (Table 2). Net survival for whites was similar to the overall 
US net survival at 1, 3, and 5 years, whereas net survival among blacks was approximately 
4% to 5% lower than that among whites at 1, 3, and 5 years. Because the general direction 
and magnitude of racial disparities were similar at 1, 3, and 5 years, we present only 5-year 
net survival estimates in the remainder of the results.
Among whites in 37 states between 2004 and 2009, 5-year net survival ranged by state from 
15.1% to 25.7% (Supporting Table 2). Among blacks in 36 states between 2004 and 2009, 5-
year net survival ranged from 7.0% to 22.7% (data for 5-year net survival among blacks 
were not available for Montana).
The pooled estimates of 5-year net survival for the US increased from 50.2% between 2001 
and 2003 to 55.1% between 2004 and 2009 for localized stage; from 20.2% to 26.4%, for 
regional stage; and from 3.6% to 4.8%, for distant stage (Table 3). In both calendar periods, 
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the US estimate of 5-year net survival was 9% to 10% lower among blacks than among 
whites for localized stage and 3% to 5% lower for regional stage. Among 34 states between 
2004 and 2009, the range in state-specific, 5-year net survival was 39.4% to 66.4% for 
patients diagnosed at localized stage, 19.1% to 34.0% for those diagnosed at regional stage, 
and 2.8% to 10.1% for those diagnosed at distant stage (Supporting Table 3) (5-year survival 
estimates by stage were not available for Maryland, Wisconsin, or Rhode Island for 2004–
2009).
Absolute Change in 5-Year Net Survival Between 2001 to 2003 and 2004 to 2009
Five-year net survival in most Northeastern states was higher than the US pooled estimate 
between both 2001–2003 and 2004–2009 (Fig. 1). In contrast, 5-year net survival in many 
states in the South, Midwest, and West was lower than the US estimate during both time 
periods. Between the periods 2001–2003 and 2004–2009, the absolute change in 5-year net 
survival increased 0.4% to 6.3% in 35 states, with a small decrease (range, 0.2%–0.3%) in 2 
states. The absolute increase was greater than 2.6% (the increase in the pooled US estimate) 
in most states in the Northeast. In contrast, the absolute increase was less than 2.6% in many 
states in the South, Midwest, and West.
Funnel Plots of 5-Year Net Survival by State
Figure 2 shows geographic and racial variation in 5-year net survival by state. Although net 
survival for lung cancer was generally low in all states, in both calendar periods, survival for 
black patients was lower than that for white patients; and, in most states, it was lower than 
the pooled estimate of US registries (see Fig. 2, horizontal line in the funnel plot).
DISCUSSION
This study provides lung cancer survival estimates by race and stage for 37 states, including 
80% of the US population. Between 2004 and 2009, the US lung cancer 5-year net survival 
was at the high end of the range for many countries in the CONCORD-2 study6 and was 
consistent with the 5-year relative survival estimates previously reported in the National 
Program of Cancer Registries and SEER registries.2
Even for a lethal cancer like lung cancer, survival for blacks was lower than for whites 
(Table 2), and this was true especially for those with localized cancer (Table 3), for which 
surgery is the main treatment of curative intent. We observed that age-standardized 5-year 
net survival for lung cancer (19.0%) was 4.2% higher than that for liver cancer (14.8%)18 
but lower than for the other cancers addressed in this Supplement, including stomach cancer 
(29.0%),19 ovarian cancer (41.0%),20 cervical cancer (62.8%),21 rectal cancer (64.0%),22 
colon cancer (64.6%),23 acute lymphoblastic leukemia in children (88.1%),24 breast cancer 
(88.6%),25 and prostate cancer (96.9%).26
Between 2004 and 2009, we observed that 5-year net survival for all stages was 4.5% lower 
among blacks than among whites. The racial differences were even more marked for lung 
cancer diagnosed at local stage (9.9% lower among blacks), 4.7% lower among blacks 
diagnosed at regional stage, but essentially the same for patients diagnosed at distant stage 
(only 0.3% lower among blacks). Our results are consistent with other reports of racial 
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disparities in lung cancer.2,17,27–29 Reviews suggest that the reasons for the wide racial 
disparities in lung cancer survival are complex and multifactorial, with contributions from 
treatment-related factors, such as physician-patient encounters and decision-making, and 
barriers to access to high-quality care, such as lower patient income or insurance coverage 
limits.30–32 Unfortunately, although our study highlights 2 key determinants (race and stage) 
of survival differences between US states, it does not provide definite conclusions about all 
of the factors that may contribute to differences, because information on these factors is not 
available for all patients with cancer at a population-based level. It would be interesting to 
analyze the availability or receipt of optimal treatment by US state and race. This may be 
possible during the next cycle of CONCORD (CONCORD-3).
In most states, we observed small but consistent increases in 5-year lung cancer net survival 
between 2001 to 2003 and 2004 to 2009, although the study only covered a single decade. 
Overall, the increase in 5-year net survival was 2.6% among whites and 1.8% among blacks. 
We also observed considerable variation in lung cancer survival between US states. Overall, 
5-year net survival ranged widely by state from 14.5% to 25.2% between 2004 and 2009, 
and ranges in survival were more extensive by stage: 39.4%–66.4% for patients diagnosed at 
localized stage, 19.1%–34.0% for those diagnosed at regional stage, and 2.8%–10.1% for 
those diagnosed at distant stage. We also observed that the change in survival between 
2001–2003 and 2004–2009 ranged from decreased survival in 2 states to an increase of up to 
6.3% in the other 35 states. Like the differences by race, our study does not enable definite 
conclusions about the explanation for the differences we observed over time and by 
geography.
Clinical Perspective
Between 2001 and 2009, several improvements occurred in clinical care for lung cancer; for 
example, increased use of video-assisted thoracic surgery,33 intensity-modulated radiation 
therapy,34 and targeted therapy, also referred to as precision or personalized treatment.35,36 
We could not directly assess whether differential access to treatment by race contributed to 
the racial disparities in survival, because we did not have data on the treatment received by 
each patient; however, if “equal treatment [for lung cancer] yields equal outcome regardless 
of race,”37 then that is a plausible conclusion.
Survival can be improved if treatment can be provided when lung cancer is diagnosed at 
localized stage.35,38 For the cancers discussed in this Supplement, only patients diagnosed at 
localized stage with liver cancer had lower 5-year survival (25.7%)18 between 2004 and 
2009 than patients diagnosed at localized stage with lung cancer (55.1%). In contrast, 
cancers commonly identified through screening tests (colon, breast, and prostate cancers) 
had the highest 5-year survival for localized stage between 2004 and 2009 (89.7%,23 98.3%,
25
 and 99.9%,26 respectively). For the other cancers in this Supplement, only ovarian cancer 
had a higher proportion of cases (56.8%)20 diagnosed at distant stage between 2004 and 
2009 than lung cancer (50.9%). Cancers commonly identified through screening tests (colon, 
breast, and prostate cancers) between 2004 and 2009 had lower proportions of cases 
diagnosed at distant stage, at 19.3%,23 5.2%,25 and 3.7%,26 respectively.
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Screening with low-dose computed tomography (CT) is now recommended by the US 
Preventive Services Task Force (USPSTF)39 for individuals at high risk for lung cancer, and 
is covered by Medicare.40 However, early detection of lung cancer by screening is unlikely 
to have contributed to the increase in 5-year net survival that we observed for lung cancer, 
because low-dose CT scans were not broadly available or recommended between 2001 and 
2009,41 and the USPSTF recommendations and Medicare regulations were only issued later.
In our study, the overall proportion of cases with unknown stage decreased from 11.5% 
between 2001 and 2003 to 8.0% between 2004 and 2009. This is an encouraging finding, 
because accurate lung cancer staging35 is needed to guide therapy selection. Although this 
decrease is consistent with an increase in accuracy over time in lung cancer staging, the 
observed changes could be an artifact related to changes in staging methods between the 2 
calendar periods. In the alternative, cases with unknown stage could be missing at random 
when some centers did not provide the data; the overall survival for these cases likely would 
be similar to the average survival for all cases. Cases with unknown stage also could reflect 
data from patients who were not completely staged because they were not good candidates 
for clinical workup and treatment; the overall survival for these cases would be similar to 
that of patients with more advanced stage disease. Between 2004 and 2009, survival for 
patients with unknown stage in our study was lower than that for patients with local or 
regional stage disease but higher than that for those with distant stage disease; this pattern 
suggests that many of the unknown cases were likely similar to cases with a more advanced 
stage.
CDC Cancer Prevention and Control Programs
The National Comprehensive Cancer Control Program (NCCCP) supports state, tribal, and 
territory programs to develop cancer plans that design and implement activities in cancer 
prevention and control.8,42 State-specific data are critical to inform these cancer-control 
plans and activities.
Although research is conducted to improve clinical care and to reduce racial disparities, the 
greatest impact to reduce lung cancer incidence will come from cancer-control efforts 
directed at primary prevention of established risk factors, such as cigarette smoking,43 the 
inhalation of secondhand smoke by nonsmokers,43 indoor radon (a leading cause of lung 
cancer among nonsmokers),44 occupational exposures to carcinogens,45 and air pollution.45
To address lung cancer prevention, incidence and mortality, NCCCP programs develop 
detailed plans to prevent and control cancer for their communities, and most include 
objectives for reducing tobacco use and indoor radon exposure. For example, two-thirds of 
NCCCP programs include funding for tobacco control, such as supporting cessation services 
and smoke-free policies.46 NCCCP programs work with a national network of partner 
organizations to reach populations that tend to be heavy smokers.47 Continued and expanded 
access to tobacco-cessation services could increase abstinence rates and decrease lung 
cancer incidence further.
Several NCCCP programs support activities related to lung cancer screening, including 
awareness through health-care provider education, media campaigns, and surveys to better 
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understand the status of lung cancer screening in their communities.48 Continued and 
expanded incorporation of objectives related to USPSTF lung cancer screening 
recommendations into NCCCP cancer plans could increase early detection of lung cancer, 
thereby improving lung cancer survival.39 NCCCP programs could use their experiences 
from other cancer screening programs to impact lung cancer screening rates at a population 
level. Furthermore, as lung cancer screening begins to be fully implemented in the United 
States, NCCCP programs might explore the use of patient navigators to coordinate and 
improve compliance with follow-up visits and annual repeated lung cancer screening.49
In the future, NCCCP programs also might consider the feasibility of monitoring and 
evaluating the quality of diagnostic, treatment, and survivorship services for patients with 
lung cancer. By improving understanding of lung cancer care and whether advances in care 
are differentially accessed, NCCCP programs may identify effective ways to improve lung 
cancer survival and reduce disparities in various communities.
NCCCP programs can use lung cancer net survival estimates for their states as an additional 
data resource to support cancer prevention and control.5,38,50 Combined with data on cancer 
incidence and death rates, cancer survival measures can provide a more comprehensive 
picture of the burden of cancer in a population and can support public health efforts to 
reduce cancer health disparities.5,38,50
Strengths and Limitations
The overview article5 by Weir et al in this Supplement of Cancer describes the strengths and 
limitations that apply to all of the articles in the Supplement, including this analysis of lung 
cancer survival.
Conclusions
We observed that lung cancer survival improved slightly from 16.4% between 2001 and 
2003 to 19.0% between 2004 and 2009 in the United States overall and in most states. It was 
low even for individuals diagnosed at localized stage (55.1%) between 2004 and 2009, and it 
was even lower among blacks (14.9%) than among whites (19.4%). We also observed 
considerable variation (range, 14.5%–25.2%) in state-specific lung cancer survival between 
2004 and 2009. Between 2001 and 2009, lung cancer incidence and mortality in the United 
States slowly decreased.1,2 Lung cancer mortality trends mirror lung cancer incidence trends 
because of the high fatality rate and low survival for patients with lung cancer.51 Given the 
low survival observed in all states, cancer-control efforts directed at primary prevention 
through control of well established risk factors would be expected to have the greatest 
impact on reducing the burden of lung cancer in the long term. Efforts directed at improving 
equality of access to treatment would be expected to reduce the racial differences in survival 
in the short to medium term.
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Figure 1. 
5-year, age-standardized net survival (%) is illustrated for adult patients (men and women 
aged 15–99 years) diagnosed with lung cancer between 2001 and 2003 and between 2004 
and 2009 with the absolute change (%). States are grouped by US Census Region and are 
ranked within Census Region by the survival estimate for 2004 to 2009. Dark colors indicate 
states affiliated with the National Program of Cancer Registries; pale colors, states affiliated 
with the Surveillance, Epidemiology, and End Results program. An asterisk indicates 
registries affiliated with both federal surveillance programs. Change (%) is not plotted if the 
survival estimate for 1 or both periods was not age standardized.
Richards et al. Page 12
Cancer. Author manuscript; available in PMC 2018 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Lung cancer 5-year, age-standardized net survival (%) is illustrated for adult patients (men 
and women aged 15–99 years) by state, race, and calendar period of diagnosis. The pooled 
US survival for each calendar period is indicated by the horizontal (solid) line.
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